CN Patent

CN101686930A — 新颖的药物组合物

Assigned to SmithKline Beecham Corp · Expires 2010-03-31 · 16y expired

What this patent protects

本发明公开了新颖的药物组合物及其制备方法，所述组合物包含3′－[(2Z)－[1－(3，4－二甲基苯基)－1，5－二氢－3－甲基－5－氧代－4H－吡唑－4－亚基]肼基]－2′－羟基－[1，1′－联苯]－3－羧酸双－(单乙醇胺)(艾曲波帕)。

USPTO Abstract

本发明公开了新颖的药物组合物及其制备方法，所述组合物包含3′－[(2Z)－[1－(3，4－二甲基苯基)－1，5－二氢－3－甲基－5－氧代－4H－吡唑－4－亚基]肼基]－2′－羟基－[1，1′－联苯]－3－羧酸双－(单乙醇胺)(艾曲波帕)。

Drugs covered by this patent

eltrombopag-olamine (ELTROMBOPAG OLAMINE)

Patent Metadata

Patent number: CN101686930A
Jurisdiction: CN
Classification: —
Expires: 2010-03-31
Drug substance claim: No
Drug product claim: No
Assignee: SmithKline Beecham Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.